Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOFA-PREDICT in psoriatic arthritis
NL-OMON54653Phase 4Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in psoriatic arthritis (PsA) comparing Tofacitinib, Methotrexate and Etanercept (3 arms). Primary endpoints: Minimal Disease Activity at week 16 and Baseline molecular network profile. Started May 2018; status: recruiting.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON54653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54653.